Plain-English translation of NCT06797193 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This study doesn't follow the usual testing phases โ it may be an observational study or a different type of research.
This trial is testing a new ultrasound imaging method called SHAPE (Subharmonic Aided Pressure Estimation) combined with a contrast medication called Definity to help doctors detect portal hypertension โ a condition where blood pressure builds up in the veins connected to your liver. The researchers want to see if this new imaging technique can reliably identify patients with this serious condition and give doctors more confidence in their diagnosis.
Portal hypertension is a serious complication of liver disease, but detecting it reliably can be difficult. This trial is exploring whether this new ultrasound imaging approach combined with the medication can give doctors a better, faster way to identify the condition without relying solely on more invasive tests.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive a single injection of the contrast medication (Definity) through an IV, followed by ultrasound imaging of your liver โ some scans will use the new SHAPE technique and some will use standard ultrasound. You will also undergo a standard liver biopsy as part of your regular care. After the imaging and biopsy are complete, you'll be monitored for about 30 minutes before you can leave.
AI-generated summary from trial data ยท Jun 9, 2026 ยท Not medical advice
United States